Showing 3561-3570 of 4164 results for "".
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Aerie Announces Positive Phase 2b Study Results for Dry Eye Product Candidatehttps://modernod.com/news/aerie-announces-positive-phase-2b-study-results-for-dry-eye-product-candidate/2480279/Aerie Pharmaceuticals reported positive topline results of its phase 2b clinical study, COMET-1, for AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The randomized, double-masked, vehicle-controlled phase 2b clinical study
- Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edemahttps://modernod.com/news/adverum-provides-update-on-advm-022-and-the-infinity-trial-in-patients-with-diabetic-macular-edema/2479404/Adverum Biotechnologies provided an update on the ADVM-022 development program following a thorough review of data available from the INFINITY clinical trial in patients with diabetic macular edema (DME) and the OPTIC clinical trial in patients with wet age-related macular degeneration (AMD). The
- ReGenTree Announces Additional Results From ARISE-3 Trial Using RGN-259 for the Treatment of Dry Eyehttps://modernod.com/news/regentree-announces-additional-results-from-arise-3-using-rgn-259-for-the-treatment-of-dry-eye/2479211/ReGenTree, a U.S. joint venture company between GtreeBNT and RegeneRx, announced results of additional analysis of the phase 3 clinical trial, ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye. In A
- Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DMEhttps://modernod.com/news/adverum-biotechnologies-reports-a-adverse-reaction-of-hypotony-in-the-infinity-trial-evaluating-advm-022-in-patients-with-dme/2479135/Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurr
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpo
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmology/2478779/Ocuphire Pharma announced that results from its ORION-1 phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma and presbyopia have been published in Clinical Ophthalmology. The paper, titled “Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil